What is being studied
Retatrutide acts at GIP, GLP-1 and glucagon receptors. Research examines combined hormone signaling in obesity and metabolic regulation.
RESEARCH PEPTIDE
Retatrutide 30 mg
In preparationExplore the listed product information and available batch documentation.
- Product name
- Retatrutide
- Listed quantity
- 30 mg
- Intended use
- Laboratory research only
- Specifications
- Not yet published
- Availability
- Not available for purchase yet
- Certificate of analysis
- Not yet published
Research reference
Metabolic signaling & body-weight research
A summary of selected literature about the substance. These are not trials of the EVALON product or instructions for use.
Published evidence
Published phase 2 and phase 3 trials studied specifically manufactured clinical formulations in adults with obesity, measuring weight outcomes and adverse events.
Limits of the evidence
Clinical-trial results do not validate the identity, safety or effectiveness of this research vial. The listed quantity is not a dosing recommendation.